All In Biotech

Drug Trial Radar · NCT00046228

A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)

A Muticenter, Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy and Safety of Reteplease and Abciximab Combination Therapy With Abciximab Alone Administered Early or Just Prior to Primary Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction.

Last checked: Nov 20, 2026Latest source record: Jul 31, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,461 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,461

Actual

Start

Aug 2002

Primary completion

Jan 2008

Study completion Jan 2008

Sponsor

Lead sponsor
Centocor, Inc.Johnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
Collaborators
Eli Lilly and Company
First posted
Sep 25, 2002

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether abciximab given in combination with reteplase, before patients have a coronary intervention (a standard treatment where a catheter is inserted into the heart artery to get blood flowing past the clot), is safe and effective in the treatment of heart attacks compared to only abciximab given during coronary intervention.

Conditions

  • Myocardial Infarction

Interventions

  • abciximab placebo; reteplase placebo, abciximab, abciximabDrug

    placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h

  • Abciximab; reteplase; abciximab placebo; abciximabDrug

    0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h

  • abciximab; reteplase placebo; abciximab placebo; abciximabDrug

    0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h

  • abciximab placebo; reteplase placebo, abciximab, abciximabDrug

    placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h

  • abciximab; reteplase placebo; abciximab placebo; abciximabDrug

    0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h

  • Abciximab; reteplase; abciximab placebo; abciximabDrug

    0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Composite of All-Cause Mortality or Complications of MI at 90 Days.Time frame: 90 days

Locations

227 sites in 19 countries. Site status is shown where the registry gives one.

  • Site not named

    Phoenix, Arizona

  • Site not named

    Covina, California

  • Site not named

    Modesto, California

  • Site not named

    Newark, Delaware

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Clearwater, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    St. Petersburg, Florida

  • Site not named

    Tallahassee, Florida

  • Site not named

    Weston, Florida

  • Site not named

    Harvey, Illinois

  • Site not named

    Rock Island, Illinois

  • Site not named

    Lexington, Kentucky

  • Site not named

    Louisville, Kentucky

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Lewiston, Maine

  • Site not named

    Worcester, Massachusetts

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Pontiac, Michigan

  • Site not named

    St Louis, Missouri

  • Site not named

    Brooklyn, New York

  • Site not named

    Flushing, New York

  • Site not named

    Mineola, New York

  • Site not named

    New York, New York

  • Site not named

    Raleigh, North Carolina

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Akron, Ohio

  • Site not named

    Cleveland, Ohio

  • Site not named

    Dayton, Ohio

  • Site not named

    Westlake, Ohio

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Tulsa, Oklahoma

  • Site not named

    Hershey, Pennsylvania

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Sayre, Pennsylvania

  • Site not named

    Sellersville, Pennsylvania

  • Site not named

    Upland, Pennsylvania

  • Site not named

    Wormleysburg, Pennsylvania

  • Site not named

    York, Pennsylvania

Showing 40 of 227 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.